Market Overview

Johnson & Johnson's Sales Slump Has Played Itself Out, Could Reaccelerate This Year

Johnson & Johnson's Sales Slump Has Played Itself Out, Could Reaccelerate This Year

JPMorgan's Michael Weinstein upgraded shares of Johnson & Johnson (NYSE: JNJ) from Neutral to Overweight with a price target boosted from $133 to $140 despite underperformance over the past year.

According to Weinstein, shares of JNJ have underperformed the past 12 months and showed investors decelerating top-line growth in 2017 due to heightened competition in the pharmaceutical unit. But the analyst believes the deceleration story has "effectively played out" as the deceleration seen in the first quarter will have "played itself out" after the second quarter.

Growth Months Away

Weinstein estimated that the Pharma's revenue growth will re-accelerate from 2.0 percent organic in the first half of 2017 to 5–6 percent in the bottom half of 2017 only to improve next year to 6–7 percent in 2018. The analyst added that his estimates would place Johnson & Johnson's growth in the pharma unit in 2018 at 2x its pharma peers at 3.2 percent. This will help the company's overall top-line growth to accelerate from 1.5 to 2.0 percent organic in the first half of 2017 to 4.0–4.5 percent in the bottom half of 2017 and 4.5–5.0 percent in 2018.

If the analyst's thesis plays out then JNJ's bottom line will accelerate from 3 to 4 percent growth in the first half of 2017 to 8–9 percent in the bottom half of 2017 and 2018.

Bottom line, While Weinstein acknowledged his upgrade to Overweight is a "notably contrarian call" there are also multiple catalysts for the Pharma business — "almost none of which" are reflected in the Street's estimates today.

Related Links:

Benzinga's Top Upgrades, Downgrades For May 15, 2017

Exclusive: Capricor CEO Talks Exondys Competition
Image Credit: By Katy Warner from Orlando, FL, USA (rapid release (02-18-08)) [CC BY-SA 2.0 (], via Wikimedia Commons

Latest Ratings for JNJ

Apr 2020BarclaysMaintainsOverweight
Apr 2020Morgan StanleyMaintainsOverweight
Apr 2020UBSDowngradesBuyNeutral

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings


Related Articles (JNJ)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas Upgrades Health Care Price Target Analyst Ratings Trading Ideas Best of Benzinga

Latest Ratings

VECOOppenheimerInitiates Coverage On18.0
NVAXJP MorganUpgrades46.0
ARYAChardan CapitalInitiates Coverage On28.0
AMCImperial CapitalMaintains4.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at